Effect of Zishen Tongyu Nangxiaoyin on Obesity Polycystic Ovary Syndrome Patients and Its Impact on Sex Hormones, Lipid Metabolism Indicators, and Hemorheology Indicators

doi:10.16458/j.cnki.1007-0893.2025.18.010

Abstract：Objective: To analyze the effect of Zishen Tongyu Nangxiaoyin in treating patients with obesity polycystic ovary syndrome (PCOS) and its impact on sex hormones, hemorheology indicators. Methods: A total of 90 patients with obesity PCOS admitted to Zhoukou Hospital of Traditional Chinese Medicine from October 2022 to October 2024 were selected as the study subjects and randomly divided into a basic group and an observation group, with 45 cases in each group. The basic group received routine treatment, while the observation group received additional Zishen Tongyu Nangxiaoyin treatment. The clinical efficacy, serum sex hormone levels, lipid metabolism indicators, hemorheology indicators, and incidence of adverse reactions before and after treatment were compared between the two groups. Results: The total effective rate of the observation group was higher than that of the basic group, with a statistically significant difference (P < 0.05). After treatment, the serum levels of testosterone (T), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in the observation group were lower than those in the basic group, with statistically significant differences (P < 0.05). After treatment, the serum levels of triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) in the observation group were lower than those in the basic group, while the high-density lipoprotein cholesterol (HDL-C) level was higher, with statistically significant differences (P < 0.05). After treatment, the plasma viscosity, whole blood low shear viscosity, and whole blood high shear viscosity in the observation group were lower than those in the basic group, with statistically significant differences (P < 0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Zishen Tongyu Nangxiaoyin combined with routine treatment can reduce sex hormone and lipid levels in patients with obesity PCOS, improve hemorheology indicators, enhance clinical efficacy, and has a high safety profile.